Indefinite Delivery Contract W911SR24D0001

The federal contract IDV award W911SR24D0001 is a single-award indefinite delivery contract issued on January 9, 2024 by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Emergent Biodefense Operations Lansing LLC, doing business as Emergent Biodefense. The contract has a ceiling value of $235,800,000.00 and a period of performance running through September 30, 2033. The purpose of this IDV is to ensure a reliable supply of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, as a critical component of the U.S. government's strategic national stockpile.

Under this IDV, the Department of the Army issued a firm fixed-price delivery order contract W911SR24F0016 to Emergent Biodefense on January 22, 2024 for the procurement of $41,801,810.00 worth of BioThrax. This 2-year delivery order contract, which does not have a set-aside designation, is meant to maintain the availability of the anthrax vaccine for national security purposes. As the prime contractor, Emergent Biodefense is responsible for manufacturing and delivering the BioThrax vaccine to the government.